Publications by authors named "Vielh P"

Background And Objective: Docetaxel has become a standard component of care for advanced prostate cancer (PC); however, its benefits are not universal among patients. A subset of PC cases exhibit TMPRSS2-ERG gene fusion, resulting in ERG overexpression in tumors. Our aim was to assess biomarkers for docetaxel efficacy in men with hormone-sensitive PC (HSPC).

View Article and Find Full Text PDF

Interventional pathology has emerged as a pivotal force in modern healthcare, heralding a paradigm shift from traditional diagnostic approaches to patient-centered care. This innovative field bridges the gap between pathology and cytopathology, empowering pathologists to streamline diagnoses and reduce waiting times for patients. Collaborative mentorship and knowledge sharing ensure a lasting legacy of diagnostic excellence for future generations.

View Article and Find Full Text PDF

Urine cytology is a noninvasive, widely used diagnostic tool for screening and surveillance of genitourinary tract neoplasms. However, the absence of unified terminology and clear objective morphological criteria limits the clinical benefit of urine cytology. The Paris System for Reporting Urine Cytology (TPS) was developed with the goal of standardizing reporting and improving urine cytology performance in detecting high-grade malignancy (HGM).

View Article and Find Full Text PDF

Introduction: The integration of whole slide imaging (WSI) and artificial intelligence (AI) with digital cytology has been growing gradually. Therefore, there is a need to evaluate the current state of digital cytology. This study aimed to determine the current landscape of digital cytology via a survey conducted as part of the American Society of Cytopathology (ASC) Digital Cytology White Paper Task Force.

View Article and Find Full Text PDF

A third update of The Bethesda System for Reporting Thyroid Cytopathology has been published in 2023 following the first (2010) and second (2017) versions. The main modifications are the following 1) a new co-Editor, 2) 4 associate editors, 3 of them from Europe, 3) the inclusion of 65 co-authors, 19 of them from Europe, 4) 2 new chapters: one dealing with pediatrics thyroid cytopathology and the other one describing molecular cytopathology profiling, 5) updated risks of malignancy (ROM), 6) a terminology in line with the 2022 WHO classification of thyroid tumors, 7) diagnostic categories now defined by a unique name, 8) 2 subtypes in the "Atypia of Undetermined Significance" category with corresponding ROM.

View Article and Find Full Text PDF
Article Synopsis
  • Standardized reporting systems in cytopathology have gained popularity for various areas like thyroid and lung over the past decade.
  • * The first edition of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was published in 2018, categorizing lesions and associating them with risk of malignancy and management strategies.
  • * The second edition, released in July 2023, updates these categories with refined risk assessments, introduces new imaging chapters, and incorporates advancements in testing and nomenclature for better diagnostic applications.
View Article and Find Full Text PDF
Article Synopsis
  • The report summarizes the November 2022 ASC/IAC Cytology Education Symposium, focusing on educational practices and opportunities for cytology students and other learners in anatomic pathology.
  • It discusses recruitment strategies for cytology programs, shares teaching resources, and highlights the role of virtual microscopy and online learning.
  • Additionally, the report addresses student wellness in schools of cytology, emphasizing the importance of mental health and support systems in educational settings.
View Article and Find Full Text PDF

Digital cytology and artificial intelligence (AI) are gaining greater adoption in the cytology laboratory. However, peer-reviewed real-world data and literature are lacking in regard to the current clinical landscape. The American Society of Cytopathology in conjunction with the International Academy of Cytology and the Digital Pathology Association established a special task force comprising 20 members with expertise and/or interest in digital cytology.

View Article and Find Full Text PDF

Digital cytology and artificial intelligence (AI) are gaining greater adoption in the cytopathology laboratory. However, peer-reviewed real-world data and literature are lacking regarding the current clinical landscape. The American Society of Cytopathology in conjunction with the International Academy of Cytology and the Digital Pathology Association established a special task force comprising 20 members with expertise and/or interest in digital cytology.

View Article and Find Full Text PDF
Article Synopsis
  • * The Atlas of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was first published in February 2018, defining six diagnostic categories to classify salivary gland lesions with associated risks and management strategies.
  • * The second edition, released in July 2023, updates malignancy risks based on comprehensive research and includes new information on imaging, testing advancements, and nomenclature.
View Article and Find Full Text PDF
Article Synopsis
  • The use of standardized reporting systems in non-gynecologic cytopathology, including thyroid and lung cytology, has significantly increased in the last decade.
  • In February 2018, the Atlas of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was launched, which includes six diagnostic categories that assess the risk of malignancy and guide clinical management.
  • The second edition of the MSRSGC, released in July 2023, updates risk assessments, adds a chapter on salivary gland imaging, and incorporates advancements in testing and naming conventions.
View Article and Find Full Text PDF

Fine-needle aspiration (FNA) cytology has been widely used for the diagnosis of breast cancer lesions with the objective of differentiating benign from malignant masses. However, the occurrence of unsatisfactory samples and false-negative rates remains a matter of concern. Major improvements have been made thanks to the implementation of rapid on-site evaluation (ROSE) in multidisciplinary and integrated medical settings such as one-stop clinics (OSCs).

View Article and Find Full Text PDF

This report highlights information and outcomes from the November 2022 ASC/IAC joint Cytology Education Symposium, an annual conference organized by the Cytology Programs Review Committee. The manuscript provides information on shared educational opportunities and practices for cytology students and other learners in anatomic pathology, discusses recruitment strategies for schools of cytology, conveys teaching resources, introduces perspectives on virtual microscopy and online learning, and transmits information about wellness of students in schools of cytology.

View Article and Find Full Text PDF

The International System for serous fluids cytopathology is a cytologic classification which purpose is to establish a consensus on diagnostic terminology. The exponential discovery of prognostic and theranostic molecular alterations in many cancers, particularly in advanced stages, led the authors to describe the indications and the feasibility of these new markers on cytological samples from serous effusions. The various immunocytochemistry techniques, FISH and those testing DNA and RNA are reported in regard to their ability to identify the main targets currently explored in routine practice.

View Article and Find Full Text PDF
Article Synopsis
  • The third edition of The Bethesda System for Reporting Thyroid Cytopathology standardizes diagnoses into six categories, with each category assigned a single name and updated risk of malignancy (ROM) based on recent data.
  • The "atypia of undetermined significance" category is simplified into two subgroups, and new information on pediatric thyroid disease, including ROMs and management, has been added.
  • The edition also aligns nomenclature with the latest World Health Organization classification and introduces chapters on molecular testing and clinical perspectives in thyroid disease.
View Article and Find Full Text PDF
Article Synopsis
  • - The third edition of The Bethesda System for Reporting Thyroid Cytopathology enhances the standardized reporting system for thyroid fine needle aspirations and introduces unified naming for six diagnostic categories with updated risk of malignancy (ROM) data.
  • - The "atypia of undetermined significance" category is simplified into two subgroups based on their ROM and molecular profiles, improving clarity in diagnosis.
  • - New chapters on molecular testing and clinical perspectives on thyroid disease have been added, along with a focus on pediatric thyroid conditions and their management.
View Article and Find Full Text PDF
Article Synopsis
  • The Sydney system was developed to improve standardization and reproducibility in lymph node cytopathology, with previous studies focusing on its risk of malignancy but not on how consistently different pathologists can interpret it.
  • A study involving 15 cytopathologists from 12 institutions globally evaluated 85 cases using digital whole-slide images, resulting in over 1200 diagnoses.
  • The findings indicated nearly perfect agreement with a ground truth for most diagnoses, but varying levels of concordance across categories, with the inadequate and malignant categories showing the most agreement, while suspicious and atypical categories had very slight agreement.
View Article and Find Full Text PDF

The International System for Serous Fluid Cytopathology is a cytologic classification which purpose is to establish a consensus on diagnostic terminology. Five diagnostic categories are proposed associated to an increased rate of malignancy and specific cytological criteria. The categories are reported as: (I) Non-diagnostic (ND), the cells are insufficient for interpretation; (II) Negative for malignancy (NFM), only benign cells are present; (III) Atypia of undetermined significance (AUS), the cells present mild atypia more likely to be benign, but a malignant process cannot be definitively excluded; (IV) Suspicious for malignancy (SFM), the cells are present with atypia or in a number suspect of malignancy but with insufficient ancillary studies to give a positive malignant diagnosis; (V) Malignant (MAL), the cytological criteria are absolutely and definitively malignant.

View Article and Find Full Text PDF

To guide the choice of treatment, every new breast cancer is assessed for aggressiveness (i.e., graded) by an experienced histopathologist.

View Article and Find Full Text PDF

Purpose: The rising cancer burden in low- and middle-income countries (LMICs) stresses already weak health care systems and poses unique challenges. In resource-constrained LMICs and in circumstances where most patients must pay out of pocket for diagnostic tests, these may not be available or affordable for many. Cytopathology provides a simple, inexpensive, standardized, and low-technology diagnostic procedure that is increasingly used as an effective tool to address the hurdles faced in cancer control programs in LMICs.

View Article and Find Full Text PDF